Records and reported status
Mar 17, 2026 FDA drug enforcement
Failed Dissolution Specifications
Class II Reported ongoing
Distribution: US Nationwide.
Official source for Xanax XR, alprazolam, extended-release tablets, 3 mg, 60 Tablets bottles, Rx only, Distributed by... Dec 23, 2024 FDA drug enforcement
Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.
Class II Reported terminated
Distribution: USA nationwide.
Official source for Cardura XL (doxazosin) extended release tablets 8 mg, 30-count bottle, Rx only, Distributed by Vi... Dec 23, 2024 FDA drug enforcement
Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.
Class II Reported terminated
Distribution: USA nationwide.
Official source for Cardura XL (doxazosin) extended release tablets 4 mg, 30 -count bottle, Rx only, Distributed by V... Nov 18, 2024 FDA drug enforcement
Superpotent Drug and Subpotent Drug: potency failures obtained
Class II Reported ongoing
Distribution: Nationwide within the United States and Puerto Rico
Official source for Levothyroxine Sodium Tablets USP, 125 mcg, packaged in a) 90-count bottles (NDC 0378-1813-77) and... Nov 18, 2024 FDA drug enforcement
Superpotent Drug and Subpotent Drug: potency failures obtained
Class II Reported ongoing
Distribution: Nationwide within the United States and Puerto Rico
Official source for Levothyroxine Sodium Tablets USP, 137 mcg, packaged in a) 90-count bottles (NDC 0378-1823-77) and... Nov 18, 2024 FDA drug enforcement
Superpotent Drug and Subpotent Drug: potency failures obtained
Class II Reported ongoing
Distribution: Nationwide within the United States and Puerto Rico
Official source for Levothyroxine Sodium Tablets USP, 150 mcg, packaged in a) 90-count bottles (NDC 0378-1815-77) and... Nov 18, 2024 FDA drug enforcement
Superpotent Drug and Subpotent Drug: potency failures obtained
Class II Reported ongoing
Distribution: Nationwide within the United States and Puerto Rico
Official source for Levothyroxine Sodium Tablets USP, 175 mcg, packaged in a) 90-count bottles (NDC 0378-1817-77) and... Nov 18, 2024 FDA drug enforcement
Superpotent Drug and Subpotent Drug: potency failures obtained
Class II Reported ongoing
Distribution: Nationwide within the United States and Puerto Rico
Official source for Levothyroxine Sodium Tablets USP, 200 mcg, packaged in a) 90-count bottles (NDC 0378-1819-77) and... Nov 18, 2024 FDA drug enforcement
Superpotent Drug and Subpotent Drug: potency failures obtained
Class II Reported ongoing
Distribution: Nationwide within the United States and Puerto Rico
Official source for Levothyroxine Sodium Tablets USP, 25 mcg, packaged in a) 90-count bottles (NDC 0378-1800-77) and ... Nov 18, 2024 FDA drug enforcement
Superpotent Drug and Subpotent Drug: potency failures obtained
Class II Reported ongoing
Distribution: Nationwide within the United States and Puerto Rico
Official source for Levothyroxine Sodium Tablets USP, 50 mcg, packaged in a) 90-count bottles (NDC 0378-1803-77) and ... Nov 18, 2024 FDA drug enforcement
Superpotent Drug and Subpotent Drug: potency failures obtained
Class II Reported ongoing
Distribution: Nationwide within the United States and Puerto Rico
Official source for Levothyroxine Sodium Tablets USP, 75 mcg, packaged in a) 90-count bottles (NDC 0378-1805-77) and ... Nov 18, 2024 FDA drug enforcement
Superpotent Drug and Subpotent Drug: potency failures obtained
Class II Reported ongoing
Distribution: Nationwide within the United States and Puerto Rico
Official source for Levothyroxine Sodium Tablets USP, 88 mcg, packaged in a) 90-count bottles (NDC 0378-1807-77) and ... Nov 18, 2024 FDA drug enforcement
Superpotent Drug and Subpotent Drug: potency failures obtained
Class II Reported ongoing
Distribution: Nationwide within the United States and Puerto Rico
Official source for Levothyroxine Sodium Tablets USP, 100 mcg, packaged in a) 90-count bottles (NDC 0378-1809-77) and... Nov 18, 2024 FDA drug enforcement
Superpotent Drug and Subpotent Drug: potency failures obtained
Class II Reported ongoing
Distribution: Nationwide within the United States and Puerto Rico
Official source for Levothyroxine Sodium Tablets USP, 112 mcg, packaged in a) 90-count bottles (NDC 0378-1811-77) and... Apr 30, 2024 FDA drug enforcement
Failed Impurities/Degradation Specifications
Class II Reported completed
Distribution: U.S. Nationwide
Official source for Cardura XL (doxazosin) extended release tablets 4mg, 30-count bottles, Rx Only, Made in Singapore... Apr 30, 2024 FDA drug enforcement
Failed Impurities/Degradation Specifications
Class II Reported completed
Distribution: U.S. Nationwide
Official source for Cardura XL (doxazosin) extended release tablets 8mg, 30-count bottles, Rx Only Made in Singapore,... Apr 25, 2024 FDA drug enforcement
Failed Tablet/Capsule Specifications: There is a potential for the imprint, M 122, to be missing on some tablets.
Class III Reported completed
Distribution: Nationwide within the united states
Official source for Valacyclovir Tablets USP, 500 mg, 90 count bottles, Rx Only, Manufactured for: Mylan Pharmaceutic... May 25, 2023 FDA drug enforcement
CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.
Class II Reported terminated
Distribution: Product was distributed to 10 distributors who may have further distribute the product to the retail level.
Official source for Levsin injection (hyoscyamine sulfate injection, USP), 0.5 mg per ml in water for Injection, 1 ml... Oct 21, 2022 FDA drug enforcement
Failed Tablet/Capsule Specifications: Tablets exceeds specification for weight and thickness.
Class II Reported terminated
Distribution: Nationwide in the USA
Official source for Carvedilol Tablets, USP, 25 mg, 500-count bottles, Rx Only, Mfg: Mylan Pharmaceuticals Inc. Morga... Oct 7, 2022 FDA drug enforcement
Presence of Particulate Matter: Product complaint for the presence of glass particles in a syringe.
Class I Reported terminated
Distribution: Nationwide in the USA
Official source for Octreotide Acetate Injection 500 mcg/mL, 10 x 1 mL Single-Dose Unit-of-Use Syringes, For Subcutan...
Reasons in these listed records Failed Dissolution Specifications Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing. Superpotent Drug and Subpotent Drug: potency failures obtained Failed Impurities/Degradation Specifications These examples come from this result page and are not a ranking of every recall reason.
Checking Viatris Inc Is there a recall on viatris inc right now? This archive contains 23 records, including 12 with agency-reported ongoing status. The status field can be incomplete or stale. Open the current official notice and match your exact product.
How do I check my package or product? Compare the product, firm and lot, date, model or serial identifiers with the notice. Use the label-check guide if you need help locating an identifier.
Does a matching name mean every item is included? A name is a search match. The agency notice sets the affected products and identifiers. Do not assume that every item with the same name or brand belongs to the recall.
What if the search finds no matching record? This search has source and keyword limits. Missing records or a missing lot code do not establish that a product is unaffected. Check source coverage and the agency's current notices.
Where can I find older records? Use monthly archives or the local search. The initial import covers records dated from October 2021 where available; each source's actual first and latest dates appear on the coverage page.